TraceLink unveils EU FMD Express

11 Apr 2018

Purpose-built compliance solution for smaller pharmaceutical companies.

TraceLink has launched EU FMD Express – a cost-effective, simplified solution designed specifically to address the needs of smaller pharmaceutical companies complying with the EU Falsified Medicines Directive (FMD.)

TraceLink unveils EU FMD Express

With far greater resource and budget constraints than their larger counterparts, many small pharmaceutical companies face extreme challenges with serialization, including master data management and data exchange with their CMOs, making it difficult to meet the EU FMD deadline by February 2019.

TraceLink’s EU FMD Express provides these companies with a simple approach to meet EU FMD compliance while controlling costs and minimizing business impact. With over 40,000 users regularly accessing the Life Sciences Cloud system, TraceLink’s EU FMD Express is a complete, easy to use solution that allows smaller manufacturers to comply with EU FMD and integrate with the EU Hub through a single, secure connection, while removing the burden of software maintenance and upgrades, and insulating companies from regulatory changes.

“Due to its size and vast number of companies spread across various countries, Europe is one of the largest and most complex markets, leaving hundreds of small companies grappling with how to achieve EU FMD compliance within the next 11 months,” said Shabbir Dahod, president and CEO, TraceLink. “As the market leader, we feel that is our responsibility to help every company comply, regardless of size, and therefore developed this cost-effective, easy to use offering to streamline the ability for smaller companies to become compliant on time, with no disruption to their business operations. Through our investment in services and support in the EU and unique network architecture to accelerate company on-boarding, TraceLink is the only company positioned to provide such an offering for this market.”

EU FMD Express: key benefits for small pharmaceutical companies

Designed specifically for smaller pharmaceutical companies with simple supply chains, EU FMD Express utilizes purpose-built templates and compliance modules for faster implementation and predictable costs. TraceLink executes the entire deployment, including system configuration and data entry. Every EU FMD Express customer will benefit from the following:
  • Easy to Use and Proven Solution That Is Purpose-Built for Smaller Companies – Enabling portal access for line management systems and CMOs with integration options available; access to TraceLink’s serial number and event repository; and direct integration into the EU Hub.
  • Simplified Deployment, Set-Up and Configuration – TraceLink Services will help EU FMD Express customers define and manage their master data, on-board and train their CMOs, configure the EU compliance module, support for QA testing and validation, and user training.
  • Ongoing Training and Education – All EU FMD Express users will have full access to TraceLink configuration templates for master data and serial number templates. TraceLink also provides an online collaboration workspace for companies to exchange customer configuration documents and full access to TraceLink University for tutorials and e-learning courses.
  • Read More

    Related news

    Spanish CDMO working ahead of EU serialisation deadline

    Spanish CDMO working ahead of EU serialisation deadline

    6 Dec 2018

    Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

    Read more 
    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    5 Dec 2018

    The financing will power the global commercial launch of the company's Fluidity One system.

    Read more 
    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    4 Dec 2018

    The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

    Read more 
    India to have strongest global growth in 2019?

    India to have strongest global growth in 2019?

    4 Dec 2018

    Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.

    Read more 
    Catalent to expand biologics packaging capabilities

    Catalent to expand biologics packaging capabilities

    3 Dec 2018

    Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.

    Read more 
    Merck successfully divests Consumer Health

    Merck successfully divests Consumer Health

    2 Dec 2018

    Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

    Read more 
    Digital manufacturing is a top priority for life sciences

    Digital manufacturing is a top priority for life sciences

    29 Nov 2018

    Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

    Read more 
    NIH to evaluate effectiveness of male contraceptive skin gel

    NIH to evaluate effectiveness of male contraceptive skin gel

    28 Nov 2018

    The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

    Read more 
    QPS expands US-based Phase I clinical trial capabilities

    QPS expands US-based Phase I clinical trial capabilities

    27 Nov 2018

    Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

    Read more 
    Hikma announces injectable licensing agreement

    Hikma announces injectable licensing agreement

    27 Nov 2018

    Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

    Read more